Simulations Plus, Inc. (NASDAQ:SLP) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its stake in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 35.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 124,002 shares of the technology company's stock after selling 68,344 shares during the period. Bank of New York Mellon Corp owned about 0.62% of Simulations Plus worth $3,458,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Barclays PLC grew its holdings in Simulations Plus by 390.6% during the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company's stock worth $911,000 after acquiring an additional 22,669 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Simulations Plus by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company's stock valued at $14,367,000 after buying an additional 18,924 shares in the last quarter. State Street Corp boosted its holdings in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company's stock valued at $20,503,000 after buying an additional 28,953 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Simulations Plus by 106.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock valued at $1,517,000 after buying an additional 24,371 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 402.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company's stock valued at $1,279,000 after buying an additional 32,002 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors.

Remove Ads

Simulations Plus Stock Up 3.6 %

Shares of Simulations Plus stock traded up $0.88 during midday trading on Friday, hitting $25.56. The company had a trading volume of 418,730 shares, compared to its average volume of 166,282. The stock has a market cap of $513.55 million, a price-to-earnings ratio of 63.90 and a beta of 0.89. The company has a fifty day simple moving average of $31.29 and a 200 day simple moving average of $30.88. Simulations Plus, Inc. has a 12-month low of $24.00 and a 12-month high of $51.22.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SLP. William Blair restated an "outperform" rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp raised their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Simulations Plus presently has an average rating of "Moderate Buy" and an average target price of $49.40.

Insider Activity at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares of the company's stock, valued at $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 19.40% of the stock is currently owned by insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.